JENNIFER TOCZYSKI: Open Payments
NPI 1356902225 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,092 in 42 payments from 14 companies in 2025. Trend: 2023 $881 · 2024 $787 · 2025 $1,092
Food & beverage: $1,058Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 19 | $529 |
| Lilly USA, LLC | 2 | $86 |
| Genentech USA, Inc. | 4 | $82 |
| CSL Behring | 3 | $79 |
| Novartis Pharmaceuticals Corporation | 2 | $54 |
| Grifols USA, LLC | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Amgen Inc. | 1 | $34 |
| GlaxoSmithKline, LLC. | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
Products named: TEZSPIRE, BREZTRI, Xolair, FASENRA, TALTZ, Hizentra, DUPIXENT, NUCALA.
Industry payments across CO — which companies pay providers there.
